Biotech is one of the most opaque categories on the public web. The science is technical, the regulatory environment shapes what can be said, and most companies bury their actual value behind investor decks and conference abstracts that AI products struggle to access. The result is a category where AI search returns inconsistent, often outdated, sometimes wrong information about who is doing what. The companies that solve this problem early are seeing meaningful benefits in BD pipeline, KOL awareness, and investor visibility. The ones still operating under old PR playbooks are losing ground without realizing it.
This piece is for communications, IR, and corporate development teams at biotech, pharma, medtech, and broader life sciences companies. It covers how AI products handle biotech queries, what the constraints are, and what specific moves build durable AEO presence in a category where the rules are different than consumer or B2B SaaS.
Why this is different
Biotech AEO operates under three constraints that make standard SEO playbooks fail.
The first is the regulatory environment. The FDA regulates promotional speech about drugs and devices through specific frameworks (off-label promotion rules, pre-approval communication restrictions, fair balance requirements). The SEC regulates investor-facing communications about clinical results, financial expectations, and forward-looking statements. State medical boards regulate physician-facing communications. Companies cannot say whatever they want about their own assets, and AEO content needs to operate within these rules.
The second is the audience. Most biotech AEO targets are not consumers. They are investors, BD professionals at potential partners, key opinion leaders, journalists at trade press, and patient advocacy organizations. Each audience uses AI products differently, asks different kinds of questions, and weighs different signals. A biotech AEO strategy that does not segment by audience produces generic content that does not work for any of them.
The third is the source ecosystem. AI products for biotech queries draw heavily from sources that other industries do not encounter. PubMed and Google Scholar for scientific evidence. ClinicalTrials.gov for trial data. SEC EDGAR filings for company-level information. Conference abstracts and posters from ASCO, AHA, AACR, JPM, and the disease-specific meetings. Trade publications run by people with science backgrounds. The retrieval system for “what does Company X do” routes through these sources before it touches the company website.
These three constraints mean biotech AEO is not just standard AEO with disclaimers. It requires its own playbook.
What investors are asking AI products
Institutional investors and retail investors are both using AI products for biotech research, with different patterns. Institutional investors use Perplexity and ChatGPT to compress the early stages of due diligence: what is this company’s pipeline, what are the recent readouts, who are the key competitors, what is the cap table situation. They cross-reference the AI output against primary sources but rely on the AI for fast orientation.
Retail investors use AI products more credulously. The questions look like “is XBio a good buy” or “what is the catalyst for YBio in Q3.” The AI’s answer (whether confident or hedged) shapes their investment decisions in ways that worry compliance teams at every public biotech.
Both audiences deserve accurate AI output. The path is making sure the underlying sources the AI draws from are accurate and current. SEC filings are usually current because they are required. Press releases are current because the company controls them. ClinicalTrials.gov registrations are often outdated, and that is fixable. Conference materials are current after they happen but rarely updated when status changes. Wikipedia articles about the company are often wrong or stale.
A quarterly audit of what the major AI tools say about the company’s pipeline and pipeline assets, followed by targeted source corrections, prevents the worst inaccuracies from compounding.
What BD professionals are asking
BD professionals at potential partners use AI products for partner discovery. The queries look like “who has Phase 2 oncology assets in glioblastoma” or “which small-molecule companies are developing TGF-beta inhibitors for fibrosis.” The AI produces a synthesized list of candidate companies, with brief summaries of their relevant assets.
For a biotech that wants to be in those lists, the path is making the relevant pipeline information surface in the underlying sources. The company website should have a clear pipeline page with the asset name, mechanism, indication, current development stage, and a brief description. The page should be discoverable (linked from the homepage, included in the sitemap, surfaced through schema). The pipeline assets should match exactly what is in ClinicalTrials.gov for ongoing trials and what is in the most recent SEC filings for stage descriptions.
Match the asset names. Inconsistency in asset naming (the trial uses one name, the press release uses another, the website uses a third) confuses the AI’s entity resolution. Pick a canonical name for each asset and use it consistently across all properties.
What KOLs are asking
Physicians and researchers (key opinion leaders) use AI products to triage information about new and emerging therapies. The queries look like “what is the mechanism of action of XBio’s lead asset” or “what were the topline results of the Phase 2 trial in indication Y.”
The accuracy bar for KOL-facing content is high because errors propagate through the medical community. The path is making sure the company’s mechanism descriptions match peer-reviewed literature, that trial result reporting matches the published or presented data, and that the company’s medical affairs team has reviewed the AEO content for scientific accuracy.
The trade press matters most for KOL queries. Coverage in STAT, Endpoints, Fierce Biotech, BioPharma Dive, and the disease-specific publications carries weight with the AI products because these outlets are read by KOLs and their writing reflects how KOLs think about the science. Earned coverage in these outlets, especially feature pieces that explain the company’s scientific approach in depth, becomes the substrate AI products draw from for KOL queries.
The pipeline page architecture
Most biotech websites have weak pipeline pages from an AEO perspective. The standard pipeline page is a chart with disease areas, asset names in boxes, and a phase progress bar. That is fine for a casual visitor but useless for AI retrieval. Each asset deserves its own page with structured information.
A complete asset page should include the asset name and any aliases (compound code, generic name, brand name when applicable), the mechanism of action with a one-paragraph scientific summary that matches published literature, the lead indication and any expansion indications, the current development stage with the specific trial citation, the geographic scope of development, the partnership status, and links to relevant clinical trials, publications, and press releases.
Use Drug or MedicalStudy schema where available. The schema vocabulary is incomplete for biotech, so some details require Article schema with descriptive properties. The structured data tells AI products that the page is about a specific molecular entity at a specific development stage.
Link the asset pages from the main pipeline page, the press releases that mention the asset, the publications page, the investor presentations, and the news section. Internal linking is a strong AEO signal because it confirms the entity exists in the company’s information architecture.
Conference and publication strategy
Major medical conferences are biotech’s biggest content moments, and most companies extract a fraction of the AEO value from them. The flow that works:
Pre-conference: A press release announcing the upcoming presentation, with the title, the session, the date, and a one-paragraph description. This release is timed to hit before the embargo and creates a discoverable marker.
During conference: A press release on the day of the presentation, with topline results (within the constraints of the embargoed data agreement). The release should include the actual data points from the abstract or poster, formatted in a way AI products can extract. Tables and lists with specific numbers (efficacy percentages, safety event rates, p-values) get cited in subsequent AI answers.
Post-conference: A blog post or technical brief on the company website that explains the data in depth, with appropriate visualizations. This becomes the canonical AEO source for the data going forward. Link from the press release. Link from the publications page. Link from the relevant asset page.
Six to twelve months later, when the data is published in a peer-reviewed journal, a third release announces the publication with the citation. Add the citation to the asset page. Link the publication to the company’s Wikidata entry (if applicable) and update any reference citations on Wikipedia.
This compound process means a single Phase 2 readout becomes one press release, one in-depth blog post, one journal article citation, and a series of references that propagate across the AI source ecosystem for years.
The Wikidata and Wikipedia layer
Wikidata is particularly important for biotech because it serves as a canonical reference for AI products on company-and-asset relationships. A biotech company with a clean Wikidata entry, properly linked to its lead assets and key trials, becomes machine-readable in a way that AI products consistently surface.
The Wikidata entry for the company should include the standard claims (instance of, founded, headquarters location, founders) plus biotech-specific properties. The “develops drug” property links the company to its pipeline assets. Each pipeline asset gets its own Wikidata entry as a chemical compound or pharmaceutical drug, with properties for mechanism, indication, development phase, and trial identifiers.
The work to create and maintain these entries pays off across every AI product that uses Wikidata as a source.
Wikipedia is harder. The notability bar for biotech companies on Wikipedia is high (well-known assets, multiple major trials, sustained coverage in major outlets), and the editorial culture is strict about promotional language. Most pre-commercial biotechs cannot sustain a Wikipedia article. Once a biotech achieves clinical or commercial milestones that meet notability standards, the article matters and should be created and maintained carefully by an experienced Wikipedia editor working at arms length from the company.
SEC filings as AEO content
The 10-K, 10-Q, and 8-K filings for public biotechs are a goldmine of AEO content most companies do not optimize. The risk factors, the pipeline descriptions, and the strategic language in these filings get cited by AI products because they are authoritative public sources.
The implication is that the language in SEC filings should be written with AI retrieval in mind, not just legal protection. The pipeline section of the 10-K should describe each asset with the same canonical name, mechanism, and stage that appears on the website. The risk factors should be specific enough to be informative without being so specific that they create exposure. The forward-looking strategy language should be consistent with the messaging in press releases and investor presentations.
This requires coordination between the IR team, legal, and communications. The teams that operate as separate silos produce filings that diverge from external messaging. The teams that coordinate produce filings that reinforce the AEO footprint.
Building the AEO function inside biotech
Biotech communications teams are typically small (one to four people) and split between IR, corporate communications, and medical affairs. AEO does not belong cleanly in any of those buckets. The function that emerges in well-run biotechs is a digital communications role that owns the website, the pipeline pages, the press release ecosystem, and the AEO measurement.
The role partners with IR on investor-facing content, with corporate communications on press releases and feature stories, and with medical affairs on scientific accuracy. The person needs enough scientific literacy to engage credibly with the medical affairs team and enough digital marketing background to execute the AEO mechanics.
For most biotechs, this is a new role. The existing IR person rarely has the time or the skill set, and the corporate communications person is usually focused on press relations rather than digital infrastructure. The right hire is someone with three to seven years of biotech communications experience and a clear track record of building digital presence.
The investment pays back. A biotech that invests in AEO over 18 to 24 months will have substantially more BD inbound, easier KOL engagement, and cleaner investor narrative than a peer company that did not. The cost is low compared to the rest of the operating budget, and the compounding nature of the work means it gets more valuable over time, not less.
The category is still early. The companies that build their AEO infrastructure in 2026 will be hard to displace by 2028. The window for cheap entry is open now and closing.